| Dr Simon Fensterszaub, DO | |
|
432 Bedford Ave, Brooklyn, NY 11249-6588 | |
| (718) 964-6161 | |
| (718) 387-9222 |
| Full Name | Dr Simon Fensterszaub |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 432 Bedford Ave, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003077322 | NPI | - | NPPES |
| 03157917 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 249846 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Granville Center For Rehabilitation And Nursing | Granville, NY | Nursing home |
| Franklin Restorative Care Center | Franklin, MN | Nursing home |
| Wabasso Restorative Care Center | Wabasso, MN | Nursing home |
| Entity Name | Qhc Upstate Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982932463 PECOS PAC ID: 5597901488 Enrollment ID: O20130419000344 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Simon Fensterszaub Do Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124460696 PECOS PAC ID: 9133403074 Enrollment ID: O20170221002238 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Suffolk Primary Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174965727 PECOS PAC ID: 9436420510 Enrollment ID: O20170808002088 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Sf New York Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679064448 PECOS PAC ID: 2668728817 Enrollment ID: O20180702001983 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Simon F Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780233569 PECOS PAC ID: 8820329527 Enrollment ID: O20191010001983 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | On Call Medical Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417599473 PECOS PAC ID: 4789019928 Enrollment ID: O20200116002519 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Infinite Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407483175 PECOS PAC ID: 8325477656 Enrollment ID: O20200407002099 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Emerald Multispecialty Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598257503 PECOS PAC ID: 5597007245 Enrollment ID: O20220317000967 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Sf Remote Medical Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235877002 PECOS PAC ID: 0042695579 Enrollment ID: O20220919002592 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Simon Medical Call Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225746068 PECOS PAC ID: 7214307818 Enrollment ID: O20221222001701 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Entity Name | Life Care Medical Ny P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821872144 PECOS PAC ID: 9032566336 Enrollment ID: O20231108001239 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Simon Fensterszaub, DO 250 Skillman St Ste 202, Brooklyn, NY 11205-1218 Ph: (718) 964-6161 | Dr Simon Fensterszaub, DO 432 Bedford Ave, Brooklyn, NY 11249-6588 Ph: (718) 964-6161 |
News Archive
Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.
Variants in a particular gene are linked with an increased risk for kidney complications in patients with lupus, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The findings could lead to better treatments to protect the kidney health of patients with the disease.
Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.
Low levels of vitamin D were associated with an increased risk of high blood pressure, high blood sugar and metabolic syndrome in teenagers, researchers reported at the American Heart Association's 49th Annual Conference on Cardiovascular Disease Epidemiology and Prevention.
› Verified 8 days ago
David Streicher, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1312 38th St, Brooklyn, NY 11218 Phone: 718-686-7600 | |
Michael Conrad, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 8012 3rd Ave, Brooklyn, NY 11209 Phone: 718-745-5600 | |
Dr. Allen L Lee, MD DIPLOMATEABFP Family Medicine Medicare: Medicare Enrolled Practice Location: 433 72nd St, Brooklyn, NY 11209 Phone: 718-748-1320 Fax: 718-321-0341 | |
Larisa Veksman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 162 Brighton 11street, 1st Floor, Brooklyn, NY 11235 Phone: 212-686-6700 Fax: 646-349-2066 | |
Oleg Kotelskiy, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3816 Nostrand Ave, Brooklyn, NY 11235 Phone: 718-338-2323 Fax: 718-338-7117 | |
Dr. Farideh Zonouzi-zadeh, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 374 Stockholm St, C/o Faculty Practice, Brooklyn, NY 11237 Phone: 718-963-6551 Fax: 718-963-6793 |